3家未盈利科创企业获得IPO注册批文，还有多家排队审核中

Group 1 - The "1+6" reform measures for the Sci-Tech Innovation Board (STAR Market) have led to the approval of IPO registration for three unprofitable companies: Wuhan Heyuan Biotechnology Co., Ltd., Guangzhou Bibet Pharmaceutical Co., Ltd., and Xi'an Yiswei Material Technology Co., Ltd. [1][2] - Heyuan Biotechnology became the first company to pass the review under the new "1+6" policy after two years of waiting, with its IPO application submitted on July 4 and registered on July 18 [1][2] - Bibet Pharmaceutical's IPO application, submitted on June 1, 2023, received registration approval on August 7, 2023, after a prolonged wait of over two years [1][2] Group 2 - Xi'an Yiswei received its registration approval on August 29, 2023, and is the first unprofitable company to be accepted under the new measures, opting for the fourth listing standard [2] - The "1+6" policy, introduced on June 18, 2023, aims to support high-quality unprofitable tech companies by reintroducing the fifth listing standard and expanding its applicability [2][3] - Shenzhen Beixin Life Technology Co., Ltd. passed the review on July 18, 2023, after being in the queue for over two years, with its IPO application submitted on March 30, 2023 [2][3] Group 3 - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. became the first company to have its IPO application accepted under the reactivated fifth listing standard on July 31, 2023 [3] - Two other companies, Harbin Sizherui Intelligent Medical Equipment Co., Ltd. and Shanghai Hengrun Da Biological Technology Co., Ltd., are still in the review process for the fifth listing standard [3] - The ChiNext board has also begun supporting high-quality unprofitable innovative companies, with the first unprofitable company, Shenzhen Dapu Microelectronics Co., Ltd., receiving acceptance on June 27, 2023 [3]